These companies could innovate their way to success.

CFOs, including Gunnar Wiedenfels of Warner Bros Discovery and Colette Kress of Nvidia, addressed disciplined spending, ...

The International Society for Stem Cell Research (ISSCR) today opened its sold-out international symposium, Accelerating ...

Data presented at ASH suggest that the CRISPR therapy could provide a one-time functional cure in children as young as 5 ...

Vertex Pharmaceuticals presents clinical data demonstrating benefits of Casgevy in SCD and TDT patients aged 5+ at ASH ...

So far, the company's commercialized drugs have delivered billions of dollars in revenue. For example, in the latest quarter, ...

Casgevy, now a "national priority" drug, helped kids with sickle cell and thalassemia, results which may help toward a label ...

Vertex Pharmaceuticals said on Saturday its gene therapy helped children aged between 5 and 11 years with sickle cell disease ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY ® (exagamglogene autotemcel) in people ages 5 years and ...

Only a couple of years since the first sickle cell disease (SCD) gene therapies gained U.S. FDA approval, researchers are working to expand access for younger children, and to improve manufacturing ...

Vertex Pharmaceuticals (NASDAQ: VRTX) has outperformed the market over the past 15 years by 6.85% on an annualized basis producing an average annual return of 18.9%. Currently, Vertex Pharmaceuticals ...